Author:
O'Sullivan J M,McCready V R,Flux G,Norman A R,Buffa F M,Chittenden S,Guy M,Pomeroy K,Cook G,Gadd J,Treleaven J,Al-Deen A,Horwich A,Huddart R A,Dearnaley D P
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kassa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365–376
2. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate- Specific Antigen Working Group. J Clin Oncol 17: 3461–3467
3. de Klerk JM, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP (1992) Pharmocokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 33: 646–651
4. de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Stokkel MP, Han SH, Blijham GH, van Rijk PP (1994a) Evaluation of thrombocytopaenia in patients treated with rhenium-186- HEDP: guidelines for individual dosage recommendations. J Nucl Med 35: 1423–1428
5. de Klerk JM, Zonnenberg BA, van het Schip AD, van Dijk A, Han SH, Quirijnen JM, Blijham GH, van Rijk PP (1994b) Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med 21: 1114–1120
Cited by
49 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献